PapersFlow Research Brief
HIV/AIDS drug development and treatment
Research Guide
What is HIV/AIDS drug development and treatment?
HIV/AIDS drug development and treatment encompasses the research on antiretroviral therapies, including integrase inhibitors, reverse transcriptase inhibitors, and nucleoside analogues, to manage HIV infection, combat drug resistance, and mitigate adverse effects such as hepatotoxicity and renal toxicity.
The field includes 68,620 works on the efficacy and safety of antiretroviral therapy for HIV infection. Key areas cover drug resistance development, use of integrase inhibitors and reverse transcriptase inhibitors, and adverse effects like hepatotoxicity and renal toxicity. Studies also examine nucleoside analogues for treating viral diseases.
Topic Hierarchy
Research Sub-Topics
HIV Integrase Inhibitors
Design, mechanism, and clinical efficacy of strand transfer inhibitors like raltegravir and dolutegravir. Researchers study resistance mutations and allosteric inhibition strategies.
Reverse Transcriptase Inhibitor Resistance
Molecular mechanisms of resistance to nucleoside and non-nucleoside RT inhibitors, including M184V mutation. Researchers develop phenotypic assays and next-generation sequencing for monitoring.
Antiretroviral Hepatotoxicity
Mechanisms of liver injury from HIV drugs like nevirapine and protease inhibitors, including mitochondrial toxicity. Researchers identify risk factors and pharmacogenomic predictors.
HIV Drug Renal Toxicity
Nephrotoxicity profiles of tenofovir and indinavir, focusing on tubular damage and glomerular injury. Researchers evaluate biomarkers and renoprotective strategies.
Nucleoside Analogues in HIV Therapy
Pharmacology and sequencing of NRTIs like zidovudine and emtricitabine in combination regimens. Researchers investigate mitochondrial effects and bone health implications.
Why It Matters
Antiretroviral therapy has driven declines in morbidity and mortality among patients with advanced HIV infection, as shown by Palella et al. (1998) who attributed reductions to more intensive therapies. Early antiretroviral therapy prevents HIV-1 sexual transmission, with Cohen et al. (2011) reporting reduced rates in the HPTN 052 trial. Zidovudine treatment in pregnant women reduced maternal-infant HIV transmission risk by approximately two-thirds, per Connor et al. (1994). Guidelines from 1998 outline principles for using these agents in HIV-infected adults and adolescents.
Reading Guide
Where to Start
'Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection' by Palella et al. (1998), as it provides foundational evidence on antiretroviral therapy's impact on patient outcomes, serving as an entry point to clinical efficacy.
Key Papers Explained
Palella et al. (1998) in 'Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection' establishes antiretroviral therapy's role in reducing AIDS-related deaths, which Cohen et al. (2011) in 'Prevention of HIV-1 Infection with Early Antiretroviral Therapy' extends to prevention via early treatment in HPTN 052. Connor et al. (1994) in 'Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment' demonstrates specific nucleoside analogue application, while 'Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents' (1998) synthesizes these into clinical protocols. Morris et al. (2009) in 'AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility' supports computational design for new inhibitors.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on computational tools like AutoDock4 for docking in integrase and reverse transcriptase inhibitor development, as per Morris et al. (2009), alongside ongoing needs to address drug resistance and toxicity noted in the field description.
Papers at a Glance
Frequently Asked Questions
What caused declining morbidity and mortality in advanced HIV patients?
Declines in morbidity and mortality due to AIDS among patients with advanced HIV infection resulted from more intensive antiretroviral therapies. Palella et al. (1998) documented these reductions in 'Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection'. The study highlighted improvements attributable to enhanced treatment regimens.
How does early antiretroviral therapy prevent HIV-1 infection?
Early initiation of antiretroviral therapy reduces rates of HIV-1 sexual transmission and clinical events. Cohen et al. (2011) in 'Prevention of HIV-1 Infection with Early Antiretroviral Therapy' showed personal and public health benefits from the HPTN 052 trial. This approach lowered transmission risks significantly.
What is the effect of zidovudine on maternal-infant HIV transmission?
Zidovudine given antepartum, intrapartum to mothers, and for six weeks to newborns reduced maternal-infant HIV transmission risk by approximately two-thirds. Connor et al. (1994) reported this in 'Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment'. The regimen applied to pregnant women with mildly symptomatic HIV and no prior treatment.
What do guidelines say about antiretroviral use in HIV-infected adults?
Guidelines provide principles for antiretroviral agent use in HIV-infected adults and adolescents. The 1998 publication 'Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents' outlines therapy standards. It focuses on managing HIV infection through structured protocols.
What role does AutoDock play in HIV drug development?
AutoDock4 and AutoDockTools4 enable automated docking with selective receptor flexibility, aiding computational drug design for HIV therapies. Morris et al. (2009) described this in 'AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility', tested on ligand-protein complexes. The tools support virtual screening in antiretroviral development.
Open Research Questions
- ? How can integrase inhibitors be optimized to prevent drug resistance in long-term HIV treatment?
- ? What mechanisms underlie hepatotoxicity and renal toxicity from reverse transcriptase inhibitors?
- ? Which nucleoside analogues most effectively target latent HIV reservoirs?
- ? How do co-receptors like those identified by Deng et al. (1996) influence primary HIV isolate entry and drug targeting?
Recent Trends
The field encompasses 68,620 works focused on antiretroviral therapy efficacy, safety, drug resistance, integrase inhibitors, reverse transcriptase inhibitors, nucleoside analogues, and adverse effects including hepatotoxicity and renal toxicity.
No recent preprints or news coverage available in the last 6 and 12 months, respectively.
Research HIV/AIDS drug development and treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HIV/AIDS drug development and treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers